Using systems pharmacology, we identified 50 anti‐HCC core targets, including EGFR, c‐Myc, ERBB2, ESR1, CCND1, and HSP90AA1, all of which play critical roles in tumor initiation, proliferation, angiogenesis, and resistance mechanisms [23, 47, 48, 49, 50, 51, 52, 53]. Here, ERBB2 is linked to neoplasm.